Last $11.53 USD
Change Today +0.16 / 1.41%
Volume 3.2M
BSX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 1:38 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Open
$11.37
Previous Close
$11.37
Day High
$11.53
Day Low
$11.35
52 Week High
01/22/14 - $14.08
52 Week Low
10/16/14 - $11.10
Market Cap
15.3B
Average Volume 10 Days
12.8M
EPS TTM
$0.41
Shares Outstanding
1.3B
EX-Date
--
P/E TM
28.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

23,000 Employees
Last Reported Date: 02/26/14
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President of Global Operations...
Total Annual Compensation: $517.7K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Kenneth J. Pucel to Leave Boston Scientific Corporation as Executive Vice President, Global Operations, Quality and Technology, Effective November 28, 2014

On September 29, 2014, Kenneth J. Pucel, Executive Vice President, Global Operations, Quality and Technology of Boston Scientific Corporation notified the company of his decision to leave the company effective November 28, 2014 in order to pursue another opportunity. Mr. Pucel will continue in his current capacity until that time and will assist in transitioning his responsibilities until his departure.

Court Orders Boston Scientific Corp. to Pay $308 Million in Damages to Mirowski Family Ventures LLC

Boston Scientific Corp. announced that a court has ordered the company to pay $308 million in damages for breaching its license agreement with Mirowski Family Ventures LLC, which owns patents related to implantable heart stimulators. In a regulatory filing, Boston Scientific said that following a jury verdict against it, the Montgomery County Circuit Court in Maryland entered a judgment that the company has breached its license agreement with Mirowski Family Ventures and awarded damages of $308 million. However, Boston Scientific noted that the facts and the law do not support the jury's findings or the amount of the damages. The company plans to seek to overturn the judgment in post-trial motions with the Circuit Court and, if necessary, through the appeals process. In September 2011, Boston Scientific filed a compliant against Mirowski in the U.S. District Court for the Southern District of Indiana for a declaratory judgment that Boston Scientific has paid all royalties owed, and did not breach any contractual or fiduciary obligations arising out of a license agreement. However, Mirowski answered and filed counterclaims requesting damages. In May 2013, Mirowski filed a complaint alleging breach of contract by Boston Scientific, in Montgomery County Circuit Court, Maryland. The complaint was amended by Mirowski in August 2013. In July 2013, the Indiana case was dismissed. In September 2013, Boston Scientific removed the case to the Maryland court. In June 2014, the District Court granted Mirowski's motion to remand the case to the Montgomery County Circuit Court, with trial commencing on September 2, 2014.

Boston Scientific Enrolls First Patients In U.S. Trial Of The Lotus(TM) Valve System

Boston Scientific Corporation has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus(TM) Valve System in patients with severe aortic stenosis and who are considered to be at either high or extreme risk for surgical valve replacement. The Lotus Valve System is the first transcatheter aortic valve replacement (TAVR) device that is both fully repositionable and retrievable prior to release. A clinical team led by Dr. Feldman implanted the first three Lotus Valve Systems this week at Evanston Hospital as part of the REPRISE III clinical trial. The initiation of the REPRISE III clinical trial marks the beginning of the process required to support U.S. Food and Drug Administration premarket approval.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $11.53 USD +0.16

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $122.81 USD +1.08
Coloplast A/S kr468.00 DKK +6.30
Olympus Corp ¥3,675 JPY +160.00
St Jude Medical Inc $58.51 USD +0.225
Terumo Corp ¥2,432 JPY +89.00
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings 64.0x
Price/Sales 2.1x
Price/Book 2.3x
Price/Cash Flow 22.9x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.